Cited by 49COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections research

Editorial: The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security

Open access
Zumla, Alimuddin, Niederman, Michael S.·2020·Current Opinion in Pulmonary Medicine

Abstract

aDivision of Infection and Immunity, Centre for Clinical Microbiology, University College London bNIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK cDivision of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, New York, USA Correspondence to Alimuddin Zumla, MD, PhD, FRCP, Division of Infection and Immunity, Centre for Clinical Microbiology, University College London Royal Free Campus, 2nd floor, Rowland Hill Street, London NW3 2PF, UK. Tel: +44 20 7472 6402; fax: +44 20 7794 0433; e-mail: [email protected].

Integrity signals

Registry

Crossref · 10.1097/mcp.0000000000000676

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The majority of antidiabetic agents, including insulin, thiazolidinediones, and insulin secretagogues, lead to body weight gain while controlling glycemia.

    “However, the majority of antidiabetic agents, including insulin, thiazolidinediones, (TZDs) and insulin secretagogues, lead to body weight gain while controlling glycemia (47–49).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zumla, A., & Niederman, M. S.
Affiliations
  • The Royal Free Hospital (GB)
  • Weill Cornell Medicine (US)
Corresponding author
Zumla, Alimuddin
Venue
Current Opinion in Pulmonary Medicine
Published
2020-05
Volume
26
Issue
3
Pages
193-196
ISSN
  • 1070-5287 (ISSN-L)
  • 1531-6971
OpenAlex
W3009042718
Cited by
49
References
37
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 9 · 2021: 11 · 2020: 18
Type
journal article
Language
en
Open access
Locations
  • Current Opinion in Pulmonary Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • National Institute for Health and Care Research (NF-SI-0616-10016)
  • National Institutes of Health
  • Horizon 2020 Framework Programme
  • European and Developing Countries Clinical Trials Partnership
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords
COVID-19 pandemic, SARS-CoV-2, respiratory infections, global health security, infectious disease outbreaks, emerging infectious diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review